Macular Edema
📧 Sign up to get email alerts when something new happens for Macular Edema.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
Vabysmo (faricimab) has been authorised by the EMA for indications including wet age-related macular degeneration, macular edema, and diabet…
-
EMA approval · 2026-08-21EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EU authorizes Rimmyrah (ranibizumab) from Qilu Pharma Spain S.L. for indications including wet age-related macular degeneration, macular ede…
-
EMA approval · 2026-08-21EMA Authorised: Eylea (aflibercept) — Bayer AG
EMA authorises Eylea (aflibercept) for multiple ocular conditions including wet age-related macular degeneration and diabetic eye diseases.
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-08-03EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
EMA authorises Vabysmo (faricimab) for wet macular degeneration, macular edema, and diabetes-related eye complications.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-03EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration…
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
-
EMA approval · 2026-06-15EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular de…
-
EMA approval · 2026-04-10EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited
The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related…
-
EMA approval · 2026-03-04EMA Authorised: Eylea (aflibercept) — Bayer AG
The EMA authorised Eylea (aflibercept) from Bayer AG for multiple ocular indications, including wet age-related macular degeneration, macula…
-
EMA approval · 2026-03-03EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH
The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edem…
-
EMA approval · 2026-02-26EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited
Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…
-
EMA approval · 2026-02-25EMA Authorised: Byooviz (ranibizumab) — Samsung Bioepis NL B.V.
EMA authorised Byooviz (ranibizumab) from Samsung Bioepis NL B.V. for multiple retinal diseases, including wet age-related macular degenerat…
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…
-
EMA approval · 2026-01-09EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…
-
EMA approval · 2026-01-06EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
The EMA authorised Vabysmo (faricimab) by Roche Registration GmbH for treatment of wet age-related macular degeneration, macular edema, and …
-
EMA approval · 2025-12-17EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited
EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, dia…
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
EMA approval · 2025-11-14EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH
Epruvy, a new marketed form of ranibizumab by Midas Pharma, has been authorised for treating wet age-related macular degeneration, macular e…
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…